Fortvita Biologics, a member of the Innovent Group, will host its first booth at a major global oncology congress at ESMO 2026. The European Society for Medical Oncology (ESMO) Annual Meeting will take place October 23–27, 2026, at IFEMA Madrid, Spain.
Fortvita leads global development of Innovent’s programs outside China, working alongside partners including Takeda. In oncology, Fortvita is advancing next-generation immuno-oncology (IO) and antibody-drug conjugate (ADC) programs, supported by expertise in protein engineering, structure-based drug design, and multispecific antibody technologies.
At ESMO 2026, Innovent will present 12 abstracts, including a Late-Breaking Abstract on the registrational Phase 3 G-HOPE-001 study of IBI343/TAK-921 (Arcotatug Tavatecan) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma. Additional presentations will feature IBI363/TAK-928 in lung cancer and gastric or gastroesophageal junction adenocarcinoma, and IBI3001 in advanced solid tumors.
See the full list of presentations, including session details in the Innovent press release.
At the Booth
Fortvita’s booth will be a space for scientific exchange on its investigational oncology programs and clinical studies, including studies with partners. Filled with plant life and accented in Fortvita’s signature green, the booth design is inspired by the company’s leaf-shaped logo.
ABOUT FORTVITA
Fortvita Biologics is a clinical-stage biopharmaceutical company headquartered in the San Francisco Bay Area, with global development and commercial operations capabilities across Asia, Europe, Australia, and the United States. As a member of the Innovent Group, Fortvita draws on Innovent Biologics’ proven discovery, development, and manufacturing capabilities. Its pipeline reflects a strong foundation in oncology that is expanding into cardiovascular and metabolic, autoimmune, and ophthalmic diseases.
Fortvita Biologics seeks strategic partnerships to accelerate the development and global accessibility of breakthrough therapies for patients worldwide. Learn more about partnering with Fortvita here.
Innovent entered into a license and collaboration agreement with Takeda for co-development and co-commercialization of IBI363 (Takeda R&D code: TAK-928), ex-China rights of Arcotatug Tavatecan (Innovent/Takeda R&D Code: IBI343/TAK-921) and an exclusive option right of IBI3001.
Forward-looking statements
This news release may contain certain forward-looking statements regarding Fortvita Biologics (“Fortvita”) that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Fortvita, are intended to identify certain of such forward-looking statements. Fortvita does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on current beliefs, assumptions, expectations, estimates, projections, and understandings of Fortvita’s management with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Fortvita’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements due to factors including, but not limited to, the timing, progress, and results of clinical trials, regulatory approvals, manufacturing capabilities, competition, and changes in political, economic, legal, and social conditions.
Fortvita, its Directors and employees assume (a) no obligation to correct or update any forward-looking statements contained in this release, and (b) no liability in the event that any of the forward-looking statements do not materialize or turn out to be incorrect.
Contact
Media:
pr@fortvitabio.com